221 related articles for article (PubMed ID: 33759677)
1. Drug metabolism in the lungs: opportunities for optimising inhaled medicines.
Enlo-Scott Z; Bäckström E; Mudway I; Forbes B
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):611-625. PubMed ID: 33759677
[TBL] [Abstract][Full Text] [Related]
2. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
3. Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases.
Matera MG; Calzetta L; Rinaldi B; Cazzola M; Rogliani P
Expert Opin Drug Deliv; 2023; 20(8):1085-1095. PubMed ID: 37715502
[TBL] [Abstract][Full Text] [Related]
4. Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery.
Martin AR; Moore CP; Finlay WH
Expert Opin Drug Deliv; 2018 Dec; 15(12):1175-1188. PubMed ID: 30388902
[TBL] [Abstract][Full Text] [Related]
5. Challenges in inhaled product development and opportunities for open innovation.
Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of inhaled drugs.
Lipworth BJ
Br J Clin Pharmacol; 1996 Dec; 42(6):697-705. PubMed ID: 8971424
[TBL] [Abstract][Full Text] [Related]
7. Current approaches to the discovery of novel inhaled medicines.
Strong P; Ito K; Murray J; Rapeport G
Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
[TBL] [Abstract][Full Text] [Related]
8. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
[TBL] [Abstract][Full Text] [Related]
9. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
Okuda T; Okamoto H
Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
[No Abstract] [Full Text] [Related]
11. Inhaling medicines: delivering drugs to the body through the lungs.
Patton JS; Byron PR
Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
[TBL] [Abstract][Full Text] [Related]
12. Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems.
Woods A; Andrian T; Sharp G; Bicer EM; Vandera KA; Patel A; Mudway I; Dailey LA; Forbes B
Eur J Pharm Biopharm; 2020 Jan; 146():64-72. PubMed ID: 31756380
[TBL] [Abstract][Full Text] [Related]
13. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
Tolman JA; Williams RO
Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
[TBL] [Abstract][Full Text] [Related]
14. Xenobiotic-metabolizing enzymes in human lung.
Zhang JY; Wang Y; Prakash C
Curr Drug Metab; 2006 Dec; 7(8):939-48. PubMed ID: 17168693
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.
Hübner M; Hochhaus G; Derendorf H
Immunol Allergy Clin North Am; 2005 Aug; 25(3):469-88. PubMed ID: 16054538
[TBL] [Abstract][Full Text] [Related]
16. Delivery strategies for sustained drug release in the lungs.
Loira-Pastoriza C; Todoroff J; Vanbever R
Adv Drug Deliv Rev; 2014 Aug; 75():81-91. PubMed ID: 24915637
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.
Guo Y; Bera H; Shi C; Zhang L; Cun D; Yang M
Acta Pharm Sin B; 2021 Aug; 11(8):2565-2584. PubMed ID: 34522598
[TBL] [Abstract][Full Text] [Related]
18. Inhaled nanoparticles--a current review.
Yang W; Peters JI; Williams RO
Int J Pharm; 2008 May; 356(1-2):239-47. PubMed ID: 18358652
[TBL] [Abstract][Full Text] [Related]
19. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
Sosnowski TR
Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
[TBL] [Abstract][Full Text] [Related]
20. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities.
Rinderknecht CH; Ning M; Wu C; Wilson MS; Gampe C
Expert Opin Drug Discov; 2024 Apr; 19(4):493-506. PubMed ID: 38407117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
